Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Merck
Harvard Business School
UBS
Federal Trade Commission
Daiichi Sankyo
AstraZeneca
Cantor Fitzgerald
Mallinckrodt

Generated: May 21, 2018

DrugPatentWatch Database Preview

Pf Prism Cv Company Profile

« Back to Dashboard

Summary for Pf Prism Cv
International Patents:1014
US Patents:42
Tradenames:11
Ingredients:11
NDAs:15

Drugs and US Patents for Pf Prism Cv

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes 8,791,140 ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-001 Sep 4, 2012 RX Yes Yes 6,002,008 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-006 Dec 30, 2004 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes 6,534,524 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Pf Prism Cv

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv TYGACIL tigecycline POWDER;IV (INFUSION) 021821-001 Jun 15, 2005 RE40183 ➤ Try a Free Trial
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-002 Sep 4, 2012 6,002,008 ➤ Try a Free Trial
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-002 May 24, 2002 5,773,443 ➤ Try a Free Trial
Pf Prism Cv VFEND voriconazole INJECTABLE;IV (INFUSION) 021267-001 May 24, 2002 5,376,645 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PF PRISM CV drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg ➤ Subscribe 2008-12-30
➤ Subscribe Tablets 50 mg and 200 mg ➤ Subscribe 2008-04-14
➤ Subscribe Tablets 1 mg and 2 mg ➤ Subscribe 2009-12-17
➤ Subscribe Oral Solution 20 mg/mL ➤ Subscribe 2010-05-19
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2010-10-08
➤ Subscribe Tablets 100mg and 500mg ➤ Subscribe 2016-09-06
➤ Subscribe Tablets 1 mg and 5 mg ➤ Subscribe 2018-02-23
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2008-09-12
➤ Subscribe For Injection 50 mg per vial ➤ Subscribe 2009-06-15
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-05-10
➤ Subscribe Tablets 0.5 mg ➤ Subscribe 2010-08-25
➤ Subscribe Injection 25 mg/mL, 1.8 mL vial ➤ Subscribe 2011-05-25
➤ Subscribe Tablets 5 mg ➤ Subscribe 2016-11-07

Non-Orange Book US Patents for Pf Prism Cv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,531,491 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use ➤ Try a Free Trial
6,028,214 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Try a Free Trial
5,608,090 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Try a Free Trial
7,803,805 Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}- -3-oxo-propionitrile mono citrate salt ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Pf Prism Cv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2008 Austria ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
C/GB02/031 United Kingdom ➤ Try a Free Trial PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
90007-1 Sweden ➤ Try a Free Trial PRODUCT NAME: AXITINIB, VALFRITT I FORM AV ETT FARMACEUTISKT GODTAGBART SALT; REG. NO/DATE: EU/1/12/777/001 20120903
0130007 00075 Estonia ➤ Try a Free Trial PRODUCT NAME: KRISOTINIIB;REG NO/DATE: K(2012)7617 LOPLIK 23.10.2012
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Boehringer Ingelheim
Chubb
Deloitte
Cerilliant
Express Scripts
Harvard Business School
McKesson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.